(EN) RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
BREVITY
NCT03524430
 Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Brigitte Poirier
Fanie Bourgault
418-525-4444 poste 82697
|
Concordance entre la biopsie liquide et la biopsie tissulaire dans les cas de cancer du sein métastatique nouvellement diagnostiqué
Concordance
NCT04241237
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Julie Lemieux
Judith-Élise Marcoux
418-525-4444 poste 84577
|
(EN) A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
EMBER-4
NCT05514054
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Brigitte Poirier
Fanie Bourgault
418-525-4444 poste 82697
|
(EN) A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
WO44263 (INAVO122)
NCT05894239
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Catherine Doyle
Fanie Bourgault
418-525-4444 poste 82697
|
(EN) A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
pionERA Breast Cancer
NCT06065748
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Julie Lemieux
Judith-Élise Marcoux
418-525-4444 poste 84577
|
(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
CAMBRIA-2
NCT05952557
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Julie Lemieux
Marie-Caude Lépine
418-525-4444 poste 82100
|
(EN) A Prospective Multi-center Clinical Study Evaluating the Use of PD G 506 A and the Eagle V1.2 Imaging System for the Visualization of Carcinoma During Breast Conserving Surgery
SBI-CIP 20-002
NCT04815083
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Christine Desbiens
Marie-Caude Lépine
418-525-4444 poste 82100
|
(EN) A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
TROPION-Breast05
NCT06103864
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dr André Blais
Marie-Caude Lépine
418-525-4444 poste 82100
|
(EN) The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
CompassHER2 RD (MAC27)
NCT04457596
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DU SAINT-SACREMENT
|
Sein |
Dre Christine Desbiens
Judith-Élise Marcoux
418-525-4444 poste 84577
|
Groupe d'étude en oncologie du Québec